These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 39213145)

  • 1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.
    Irving PM; Hur P; Gautam R; Guo X; Vermeire S
    J Manag Care Spec Pharm; 2024 Sep; 30(9):1026-1040. PubMed ID: 39213145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.
    Reinisch W; Melmed GY; Nakase H; Seidelin J; Ma C; Xuan S; Tran J; Remple V; Wegrzyn L; Levy G; Sanchez Gonzalez Y; Panaccione R
    Adv Ther; 2024 Oct; 41(10):3832-3849. PubMed ID: 39126596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
    Wu B; Wang Z; Zhang Q
    Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis.
    Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD
    Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Jan; 47(2):162-175. PubMed ID: 29205406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
    Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
    Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review.
    Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R
    BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
    Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study.
    Straatmijer T; Biemans VBC; Visschedijk M; Hoentjen F; de Vries A; van Bodegraven AA; Bodelier A; de Boer NKH; Dijkstra G; Festen N; Horjus C; Jansen JM; Jharap B; Mares W; van Schaik FDM; Ponsioen C; Romkens T; Srivastava N; van der Voorn MMPJA; West R; van der Woude J; Wolvers MDJ; Pierik M; van der Meulen-de Jong AE; Duijvestein M;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):182-191.e2. PubMed ID: 35644343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
    Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
    United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Buisson A; Nachury M; Guilmoteau T; Altwegg R; Treton X; Fumery M; Serrero M; Leclerc E; Caillo L; Pereira B; Amiot A; Bouguen G
    Aliment Pharmacol Ther; 2023 Mar; 57(6):676-688. PubMed ID: 36401585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
    Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
    J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.
    Fumery M; Serrero M; Bouguen G; Amiot A; Altwegg R; Nachury M; Vuitton L; Treton X; Caillo L; Pereira B; Buisson A
    J Crohns Colitis; 2024 Oct; 18(10):1615-1621. PubMed ID: 38742654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.